Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
Addition of atezolizumab to trastuzumab emtansine might potentiate anticancer immunity and enhance the HER2-targeted cytotoxic activity. The KATE2 study is a randomised, double-blind, placebo-controlled, phase 2 study at 68 centres in nine countries. The addition of atezlizumb to trastuzumab emtansine did not show a clinically meaningful improvement in progression-free survival.
